FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596359635> ?p ?o ?g. }

• W2596359635 abstract "Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) represent 15-20% of childhood/adolescent young adults (AYA) ALL. An intensive chemotherapy is generally needed to obtain the same results than in B-lineage ALL. Day 8 Poor Prednisone Response (PPR) and early resistant disease (refractoriness after induction course or MRD level >10-3 at time point 1 (TP1) and/or TP2) remain particularly challenging as relapses are very difficult to treat especially if they occur early. Nelarabine is a water-soluble prodrug of araG (9-B-arabinofuranosylguanine) which is cytotoxic to T lymphoblasts due to the accumulation of araG nucleotides, especially araGTP, which result in inhibition of ribonucleotide reductase and inhibition of DNA synthesis. Nelarabine was shown to be effective and safe in phase II-III adult and pediatric ALL trials. We describe here a 7 consecutive years experience of nelarabine in “real life” in 3 pediatric / AYA centers. Methods: All children and AYA who received nelarabine in first line therapy or after relapse between 2006 and 2013 were reviewed retrospectively. Classical initial prognostic factors were collected: age, leucocytosis, CNS status, day 8 prednisone response, complete remission (CR) or not, minimum residual disease (MRD) level at TP1 and TP2. Eighty two % of the patients (pts) followed the French FRALLE 2000-T recommendations. Nelarabine, alone or in combination, was used in two groups of pts: group 1: pts in whom nelarabine is given in first line therapy because of high MRD level >10-3 at TP1 and/or TP2 (whatever the level at time of nelarabine infusion) and pts refractory to induction course, and group 2: pts in relapse. Group 1 and 2 are compared for MRD level after nelarabine, number of patients able to go to allogeneic HSCT and overall survival. Finally the safety profile was assessed. Results: 33 T-ALL patients received nelarabine alone (n= 22) or in combination (n= 11, most often with cyclophosphamide and etoposide) from 2006 to 2013. At initial diagnosis, median age was 11.6 y old [3-24], sex ratio 4.5 (M/F 27/6) and median leukocytosis 184.7.109/L [0.1-914]. These patients shared poor risk factors: CNS3 (n=8, 24.1%), D8 PPR (n=23, 69.7%), day 21 M3 bone marrow (n=13, 36.4%), no CR after one induction course (n=6, 18.2%) and MRD level > 10-3 at CR1 (n=15, 42.4%). Regarding group 1 (high MRD level at TP1 and/or TP2 n= 11, refractoriness to induction course n= 5), the status just before nelarabine was: 6 in CR1 with finally MRD <10-3, 5 in CR1 but MRD >10-3 and 5 refractory. Nelarabine was given alone in 12 patients and in combination in 4 patients. MRD level after nelarabine was <10-3 in 12/16 patients. Overall, 11 pts received an allogeneic HSCT and 13/16 (81%) are alive in CR1 at the time of the analysis with a median FU from first nelarabine infusion of 13.7 months [0.8-58.3]. Overall survival is 79.8%+/-10.5 at 5 years. Regarding group 2 (relapsed patients, n= 17), nelarabine was infused at the time of first relapse in 4 patients and in refractory first relapse or more than first relapse in 13 patients. Among these heavily pretreated patients, only 6 obtained a MRD level <10-3 leading to allogeneic HSCT but none of 6 survived. Only one patient survived in CR3 after a success of nelarabine alone and received other chemotherapy without allogeneic HSCT. Regarding toxicities, the only WHO grade III-IV observed side effects are cytopenias (n= 25, 75.8%). Others reported side effects are limited (grade I-II): fever of undetermined origin or infections (n= 7, 21.2%), neurological (n= 6 pts, 18.2%; some of them with more than one side effect: sensory neuropathy in 4, motor neuropathy in 2, headaches in 2, motor-facial neuropathy in 1, ataxia in 1) or muscular (n= 4, 12.1%; 2 myalgia, 1 myositis, 1 amyotrophia), liver toxicities (n= 4, 12.1%; 3 transaminase increases, 1 hyperbilirubinemia). Conclusions: In a non selected population of childhood / AYA high-risk T-ALL, nelarabine was very useful for poor risk patients in first line therapy. The majority of patients received nelarabine as a monotherapy. By contrast nelarabine mostly failed to improve the survival in heavily pretreated relapsed patients. Overall, this study conforts the use of nelarabine in first line T-ALL and high-risk features with acceptable tolerance. The evaluation of nelarabine in selected high-risk patients in a first line setting should be evaluated prospectively to confirm these results. Disclosures Baruchel: JAZZ: Membership on an entity's Board of Directors or advisory committees; ARIAD: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees." @default.
• W2596359635 created "2017-03-23" @default.
• W2596359635 creator A5005516784 @default.
• W2596359635 creator A5011992727 @default.
• W2596359635 creator A5019776300 @default.
• W2596359635 creator A5038791283 @default.
• W2596359635 creator A5038808668 @default.
• W2596359635 creator A5040756049 @default.
• W2596359635 creator A5047925131 @default.
• W2596359635 creator A5064658190 @default.
• W2596359635 creator A5076973611 @default.
• W2596359635 creator A5078705132 @default.
• W2596359635 creator A5090219178 @default.
• W2596359635 date "2014-12-06" @default.
• W2596359635 modified "2023-10-18" @default.
• W2596359635 title "Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia" @default.
• W2596359635 doi "https://doi.org/10.1182/blood.v124.21.3723.3723" @default.
• W2596359635 hasPublicationYear "2014" @default.
• W2596359635 type Work @default.
• W2596359635 sameAs 2596359635 @default.
• W2596359635 citedByCount "0" @default.
• W2596359635 crossrefType "journal-article" @default.
• W2596359635 hasAuthorship W2596359635A5005516784 @default.
• W2596359635 hasAuthorship W2596359635A5011992727 @default.
• W2596359635 hasAuthorship W2596359635A5019776300 @default.
• W2596359635 hasAuthorship W2596359635A5038791283 @default.
• W2596359635 hasAuthorship W2596359635A5038808668 @default.
• W2596359635 hasAuthorship W2596359635A5040756049 @default.
• W2596359635 hasAuthorship W2596359635A5047925131 @default.
• W2596359635 hasAuthorship W2596359635A5064658190 @default.
• W2596359635 hasAuthorship W2596359635A5076973611 @default.
• W2596359635 hasAuthorship W2596359635A5078705132 @default.
• W2596359635 hasAuthorship W2596359635A5090219178 @default.
• W2596359635 hasConcept C126322002 @default.
• W2596359635 hasConcept C143998085 @default.
• W2596359635 hasConcept C187212893 @default.
• W2596359635 hasConcept C205545832 @default.
• W2596359635 hasConcept C2778461978 @default.
• W2596359635 hasConcept C2778720950 @default.
• W2596359635 hasConcept C2779823535 @default.
• W2596359635 hasConcept C2781107101 @default.
• W2596359635 hasConcept C2909962599 @default.
• W2596359635 hasConcept C71924100 @default.
• W2596359635 hasConceptScore W2596359635C126322002 @default.
• W2596359635 hasConceptScore W2596359635C143998085 @default.
• W2596359635 hasConceptScore W2596359635C187212893 @default.
• W2596359635 hasConceptScore W2596359635C205545832 @default.
• W2596359635 hasConceptScore W2596359635C2778461978 @default.
• W2596359635 hasConceptScore W2596359635C2778720950 @default.
• W2596359635 hasConceptScore W2596359635C2779823535 @default.
• W2596359635 hasConceptScore W2596359635C2781107101 @default.
• W2596359635 hasConceptScore W2596359635C2909962599 @default.
• W2596359635 hasConceptScore W2596359635C71924100 @default.
• W2596359635 hasLocation W25963596351 @default.
• W2596359635 hasOpenAccess W2596359635 @default.
• W2596359635 hasPrimaryLocation W25963596351 @default.
• W2596359635 hasRelatedWork W2110056604 @default.
• W2596359635 hasRelatedWork W2246803817 @default.
• W2596359635 hasRelatedWork W2477239645 @default.
• W2596359635 hasRelatedWork W2546713081 @default.
• W2596359635 hasRelatedWork W2555678589 @default.
• W2596359635 hasRelatedWork W2557413167 @default.
• W2596359635 hasRelatedWork W2582438760 @default.
• W2596359635 hasRelatedWork W2583040475 @default.
• W2596359635 hasRelatedWork W2586089700 @default.
• W2596359635 hasRelatedWork W2615082464 @default.
• W2596359635 hasRelatedWork W2742925810 @default.
• W2596359635 hasRelatedWork W2743267453 @default.
• W2596359635 hasRelatedWork W2784828107 @default.
• W2596359635 hasRelatedWork W2908792704 @default.
• W2596359635 hasRelatedWork W2941471400 @default.
• W2596359635 hasRelatedWork W2979306119 @default.
• W2596359635 hasRelatedWork W2980060245 @default.
• W2596359635 hasRelatedWork W3015241637 @default.
• W2596359635 hasRelatedWork W3017355756 @default.
• W2596359635 hasRelatedWork W3048707350 @default.
• W2596359635 isParatext "false" @default.
• W2596359635 isRetracted "false" @default.
• W2596359635 magId "2596359635" @default.
• W2596359635 workType "article" @default.